What is Prostate Cancer Market?
Prostate Cancer is type of cancer mainly found in male’s Prostate glands. It is minor walnut-shaped gland in men that produces the seminal fluid that sustains and carriages sperm. Prostate cancer is start when cells are begin to grow out of control in the prostate gland. There are main two type of prostate cancer hormone sensitive prostate cancer and hormone refractory prostate cancer. Other type of prostate cancer are sarcomas, small cell carcinomas, neuroendocrine tumors and transitional cell carcinomas. Burning or pain during urination. Rising trouble urinating, difficulty in starting and stopping while urinating and frequent urges to urinate at night are some symptoms of the prostate cancer.
The market study is being classified by Type (Hormone sensitive prostate cancer and Hormone refractory prostate cancer), by Application (Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy) and major geographies with country level break-up.
Astellas, Inc. (Japan), AstraZeneca plc. (United Kingdom), Johnson & Johnson (United States), Sanofi S.A (France), Bristol Myers Squibb (BMS) (United States), Bayer AG (Germany), Abbott (United States), BioMark Diagnostics Inc. (Canada), Sanofi (France) and Ipsen (France) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are TOLMAR Pharmaceuticals Inc. (United States) and Indevus Pharmaceuticals Inc. (United States).
Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Prostate Cancer market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Prostate Cancer market by Type, Application and Region.
On the basis of geography, the market of Prostate Cancer has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increasing Availability of Enhanced Diagnosis Centers in Emerging Countries
- Rising Awareness about the Treatment
- Growing Dependency on Advanced Drugs
- Adoption of Advance Oncology Diagnostics Technology
- High Prices
- Lengthy Treatment Periods
- Rising Treatment Facility in Rural Regions of Developing Countries
Market Leaders and some development strategies
On 23rd January 2018, Astellas Pharma Inc. has acquired Mitobridge, Inc. (a biotechnology company, discovers and develops novel small molecule therapeutics that improve mitochondrial functions). The deal was established for 225 million dollar.
On 29th October 2018, Astellas Pharma Inc. has announced that they get approval from European Commission (EC) for a new indication for XTANDI. This XTANDI (enzalutamide) is used for treatment of adult men with high-risk, non-metastatic, castration-resistant prostate cancer.
Key Target AudienceProstate Cancer Treatment Provider, Health care Industry, Pharmaceutical Industry, Medical Research Institutes, Government and Private Research Institutes and Others